{
    "title": "Novartis, GBT sickle cell drugs too expensive, draft U.S. report says",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-7925955/Novartis-GBT-sickle-cell-drugs-expensive-draft-U-S-report-says.html",
    "date": "2020-01-24",
    "keywords": [
        "icer",
        "disease",
        "costeffectiveness",
        "cell",
        "novartis",
        "gbt",
        "year",
        "health",
        "miller",
        "draft",
        "report",
        "institute",
        "emmaus",
        "cost",
        "oxbryta",
        "group",
        "treatment",
        "comment",
        "sickle",
        "premature",
        "blood",
        "friday",
        "debate",
        "review",
        "adakveo",
        "finding",
        "congress",
        "president",
        "action",
        "healthcare",
        "reimbursement",
        "bill",
        "driver",
        "publication",
        "life",
        "qaly",
        "gain",
        "qalys",
        "pain",
        "scd",
        "understanding",
        "approach",
        "assessment",
        "value",
        "food",
        "drug",
        "goal",
        "access",
        "price",
        "effectiveness",
        "gene",
        "therapy",
        "bluebird",
        "bio",
        "inc",
        "interest",
        "half",
        "government",
        "insurance",
        "reporting",
        "john",
        "editing",
        "fenton"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}